Inventor · disambiguated record
Jeffrey A. Medin
Also filed as: MEDIN JEFFREY · MEDIN JEFFREY A
15 granted patents·18 pending applications·33 citations·filing 2002–2025
90Inventor score
Files withMEDICAL COLLEGE WISCONSIN INC9UNIV HEALTH NETWORK9MEDIN JEFFREY A8MEDICAL COLLEGE OF WISCONSIN INC5FOWLER DANIEL1
Top patents by PatentIndex Score
33 records- 0187US11667721B2CD30 bispecific antibodies and method of immunotherapy of CD30+ malignanciesMEDICAL COLLEGE OF WISCONSIN INC·Filed 2019·Granted Jun 6, 2023·4 cites·17 claims
- 0286US8765462B2IL-12 immunotherapy for cancerMEDIN JEFFREY A·Filed 2008·Granted Jul 1, 2014·13 cites·12 claims
- 0381US10022405B2IL-12 immunotherapy for cancerUNIV HEALTH NETWORK·Filed 2016·Granted Jul 17, 2018·3 cites·20 claims
- 0480US11597917B2In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2018·Granted Mar 7, 2023·2 cites·26 claims
- 0579US11584799B2Anti-CD30 antibodies and methods for treating CD30+ cancerMEDICAL COLLEGE OF WISCONSIN INC·Filed 2019·Granted Feb 21, 2023·4 cites·19 claims
- 0679US2025346680A1System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignanciesMEDICAL COLLEGE OF WISCONSIN INC·Filed 2025·Application pending·0 cites
- 0776US12391764B2Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignanciesMEDICAL COLLEGE OF WISCONSIN INC·Filed 2023·Granted Aug 19, 2025·0 cites·34 claims
- 0876US8568709B2Thymidylate kinase fusions and uses thereofMEDIN JEFFREY A·Filed 2009·Granted Oct 29, 2013·3 cites·17 claims
- 0972US2023332112A1Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of DisordersMEDICAL COLLEGE WISCONSIN INC·Filed 2023·Application pending·0 cites
- 1071US2025277050A1Anti-cd30 antibodies and methods for treating cd30+ cancerMEDICAL COLLEGE WISCONSIN INC·Filed 2025·Application pending·0 cites
- 1170US12351639B2Anti-CD30 antibodiesMEDICAL COLLEGE OF WISCONSIN INC·Filed 2023·Granted Jul 8, 2025·0 cites·43 claims
- 1269US8445635B2Modified H2 relaxin for tumor suppressionMEDIN JEFFREY A·Filed 2007·Granted May 21, 2013·3 cites·35 claims
- 1368US9439980B2Thymidylate kinase fusions and uses thereofUNIV HEALTH NETWORK·Filed 2013·Granted Sep 13, 2016·1 cites·16 claims
- 1465US2025188428A1Novel in vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced hscs for therapy of disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2025·Application pending·0 cites
- 1561US12239693B2Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2019·Granted Mar 4, 2025·0 cites·12 claims
- 1661US12076344B2T-Rapa cells as novel effector cell type for chimeric antigen receptor therapyMEDICAL COLLEGE WISCONSIN INC·Filed 2019·Granted Sep 3, 2024·0 cites·19 claims
- 1761US2020038457A1Il-12 immunotherapy for cancerUNIV HEALTH NETWORK·Filed 2019·Application pending·0 cites
- 1860US2011027310A1Compositions and Methods for Cancer TreatmentMEDIN JEFFREY A·Filed 2008·Application pending·0 cites
- 1959US2014370039A1Il-12 immunotherapy for cancerUNIV HEALTH NETWORK·Filed 2014·Application pending·0 cites
- 2058US2014193449A1Compositions and methods for cancer treatmentUNIV HEALTH NETWORK·Filed 2014·Application pending·0 cites
- 2156US10258653B2IL-12 immunotherapy for cancerUNIV HEALTH NETWORK·Filed 2015·Granted Apr 16, 2019·0 cites·11 claims
- 2254US2010233200A1Vector encoding therapeutic polypeptide and safety elements to clear transduced cellsMEDIN JEFFREY A·Filed 2008·Application pending·0 cites
- 2354US2025170221A1Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2025·Application pending·0 cites
- 2452US12006511B2Recombinant PD-L1 peptides and methods of useMEDICAL COLLEGE WISCONSIN INC·Filed 2020·Granted Jun 11, 2024·0 cites·15 claims
- 2552US10137205B2Thymidylate kinase fusions and uses thereofUNIV HEALTH NETWORK·Filed 2016·Granted Nov 27, 2018·0 cites·9 claims
- 2651US2016250309A1Compositions and methods for cancer treatmentUNIV HEALTH NETWORK·Filed 2016·Application pending·0 cites
- 2750US2023280344A1Multiple Myeloma Mapping and Uses ThereofMEDICAL COLLEGE WISCONSIN INC·Filed 2021·Application pending·0 cites
- 2849US2009074733A1Thymidylate kinase mutants and uses thereofMEDIN JEFFREY A·Filed 2006·Application pending·0 cites
- 2948US2011014165A1Thymidylate Kinase Mutants and Uses ThereofMEDIN JEFFREY A·Filed 2010·Application pending·0 cites
- 3048US2009068158A1Thymidylate kinase mutants and uses thereofMEDIN JEFFREY A·Filed 2008·Application pending·0 cites
- 3143US2004258661A1Generation of use of tc1 and tc2 cellsFiled 2002·Application pending·0 cites
- 3241US2016074533A1Vector encoding therapeutic polypeptide and safety elements to clear transduced cellsUNIV HEALTH NETWORK·Filed 2015·Application pending·0 cites
- 3333US2012251514A1Modulated programmed death ligand-1FOWLER DANIEL·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey A. Medin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →